Loading...
Brentuximab vedotin is an anti-CD30 antibody–drug conjugate approved for patients with relapsed Hodgkin lymphoma (HL). To test its role as front-line therapy, investigators conducted an industry-sponsored, international, randomized phase III trial in which 1334 patients with newly-diagnosed, advanced-stage HL received standard ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine) or the same regimen with brentuximab vedotin substituted for bleomycin (AAVD). The primary endpoint was modified progression-free survival (mPFS), defined as time to death, progression, or incomplete response requiring alternative anti-lymphoma therapy.
At a median follow-up of 24.9 months, mPFS was significantly improved with AAVD versus ABVD (82.1% vs. 77.2%; P=…